Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis.
about
The Natural Course of Non-Alcoholic Fatty Liver DiseaseType 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the SpotlightChemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agentsContribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinomaAdvances in hepatocellular carcinoma: Nonalcoholic steatohepatitis-related hepatocellular carcinomaNon-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval PathwayContributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancerPrevention of Hepatocellular CarcinomaFatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIVNASH Cirrhosis - the New Burden in Liver Transplantation: How Should It Be Managed?Endoplasmic reticulum stress activates the hepatic activator protein 1 complex via mitogen activated protein kinase-dependent signaling pathwaysNon-invasive separation of alcoholic and non-alcoholic liver disease with predictive modelingThe global epidemiology of hepatocellular carcinoma: present and futureHepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management.Non-alcoholic fatty liver disease: epidemiology, clinical course, investigation, and treatment.Effects of Bariatric Surgery on Non-alcoholic Fatty Liver Disease: Magnetic Resonance Imaging Is an Effective, Non-invasive Method to Evaluate Changes in the Liver Fat Fraction.Characterization and prognosis of patients with hepatocellular carcinoma (HCC) in the non-cirrhotic liverMetabolic syndrome and non-alcoholic fatty liver disease in liver surgery: The new scourges?SREBP-1 has a prognostic role and contributes to invasion and metastasis in human hepatocellular carcinomaNonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options.Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease.Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse.Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetesAssociation between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review.Global Inactivation of the Pla2g6 Gene in Mice Does Not Cause Dyslipidemia under Chow or High-fat Diet Conditions.Fibrogenesis and Carcinogenesis in Nonalcoholic Steatohepatitis (NASH): Involvement of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinase (TIMPs).Loss of 5α-reductase type 1 accelerates the development of hepatic steatosis but protects against hepatocellular carcinoma in male mice.Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans.Recent advances in the development of farnesoid X receptor agonistsClinical features and outcome of cryptogenic hepatocellular carcinoma compared to those of viral and alcoholic hepatocellular carcinoma.The Gordian Knot of dysbiosis, obesity and NAFLD.Association of nonalcoholic fatty liver disease and liver cancer.Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease.Association between metabolic abnormalities and HBV related hepatocelluar carcinoma in Chinese: a cross-sectional study.Evaluation of Biomarkers of NAFLD in a Cohort of Morbidly Obese Patients.Decrypting cryptogenic hepatocellular carcinoma: clinical manifestations, prognostic factors and long-term survival by propensity score model.Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study.Liver Injury Indicating Fatty Liver but Not Serologic NASH Marker Improves under Metformin Treatment in Polycystic Ovary Syndrome.HCC, diet and metabolic factors: Diet and HCCTreatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma.
P2860
Q26746947-847C2562-9252-4BDB-B9D7-EC96B75EB56AQ26752583-03E7B784-B72B-4A66-B7CE-3E1B4BE8B2D4Q26772302-7F4B9700-7203-4BA2-91D4-5FA64B20DD02Q26781477-6EF8713D-623E-4A24-8B75-A60668061AC2Q26795529-3C755F44-A523-4F34-A905-3CB05833DB89Q26800894-F632570E-EE96-4D79-B44A-78F60991982DQ26992106-4F9797A0-86F4-4F9F-B881-B492CAD8DBE3Q28079576-F5A2F1CE-9246-40A0-8BEF-5D8639FD44BAQ28079826-95D92C8B-5CA4-4AAE-9632-7609DDED8ED2Q28079900-9D5C1761-EF50-4078-B5AA-BC47D0173FD4Q28391490-F95635BF-7BBF-452A-8A19-609F06C97385Q28540257-FB0C0901-B1BC-4218-B387-1A817ABC40C7Q28654353-A4A826ED-FE44-4011-9F51-503901A2F953Q30234574-DA8A8DA7-AB61-4D3A-A069-328751A5D729Q30434684-709B3877-CD37-409E-9E4A-1FD26443E60CQ31153508-8CE22ED8-DA64-4B65-95DC-4BD5E821A5C6Q31170677-30EF93B6-CDD6-4478-89A3-B7DC09757B10Q33660027-E1D1A836-AFA0-4532-B5D7-28B4080866B5Q33755503-50C0D976-A42B-436A-A477-43C39A7D52F6Q33855157-0468413C-E4DA-47E8-9BFF-D63DDC1C45F0Q33886948-AF0FF958-A81F-4307-AEF0-2D9D57073FC2Q34185231-3BFBD013-A8D2-46A5-8866-A3A72761BCAEQ34205386-B30E99B2-26A7-4B3C-BC73-1860E6991AD4Q34304174-49BBF842-58B7-4532-A4EE-E5C398CA8EADQ34305395-C64DBBEA-AF7A-481F-829C-9A5611DF97B1Q34309876-C05D2B23-5B43-415A-A9C3-20A01E309403Q34316501-67042EA6-4FAB-4AF4-975E-61A01C5CAE30Q34323499-60C4D722-3551-4883-BA69-924239638188Q34464043-3D60722C-6EEF-49AA-A270-14F83CE069ADQ34799936-DD15B315-3792-4971-9CD8-945E34BA3677Q34956813-8CFA80E1-2A91-4F6E-AC45-3CE9741C22C7Q34986030-A0B911FC-6E87-444D-8646-EE34DD04F221Q35012074-5B631474-3D25-45B5-ACF8-D8CD267E1F66Q35054630-293324FC-79A5-4862-BF73-178FD6797C75Q35101419-E67A63F3-FC5F-437B-9577-3C76775F8091Q35107166-667418BD-0C34-4402-90CC-5E35A6668525Q35156568-A7B7F530-76DB-47ED-8F75-5C45E60E528CQ35250192-8BEB3649-E45B-42C4-A3A3-CA80346BF12FQ35507651-710DBDA7-325A-4A2F-AC0B-B7D023401AEDQ35531154-EA6E35E5-A322-4CC9-AB20-2B7360AEB903
P2860
Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Non-alcoholic fatty liver dise ...... absence of apparent cirrhosis.
@en
Non-alcoholic fatty liver dise ...... absence of apparent cirrhosis.
@nl
type
label
Non-alcoholic fatty liver dise ...... absence of apparent cirrhosis.
@en
Non-alcoholic fatty liver dise ...... absence of apparent cirrhosis.
@nl
prefLabel
Non-alcoholic fatty liver dise ...... absence of apparent cirrhosis.
@en
Non-alcoholic fatty liver dise ...... absence of apparent cirrhosis.
@nl
P2093
P2860
P50
P356
P1476
Non-alcoholic fatty liver dise ...... absence of apparent cirrhosis
@en
P2093
Alexander Dechêne
Gernot Kaiser
Judith Ertle
Kerstin Herzer
Volker Penndorf
Wing-Kin Syn
P2860
P304
P356
10.1002/IJC.25797
P577
2011-03-14T00:00:00Z